Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
Ihab Weheba,Abeer Mohamed Abdelsayed,Rand Khaled Arnaout,Mohamed Omar Zeitouni,Khalid Fahad Mobaireek,Tahani Bakheet AlHarthi,Abdullah Mobeireek +6 more
TL;DR: Despite several benefits, notably a reduction in utilization of health services and asthma medication, anti-IgE therapy is probably underutilized locally and there is room for improvement in the prescription practices, particularly in dosing and the setting for delivery.
Journal ArticleDOI
Bronchial asthma developing after 15 years of immunosuppressive treatment following renal transplantation.
TL;DR: A 42-year-old woman who underwent renal transplantation from her mother at the age of 26 due to IgA nephropathy developed bronchial asthma for the first time after performing house-cleaning activities and was treated with corticosteroids and antiasthmatic agents.
Book ChapterDOI
Target Selection and Validation in Drug Discovery
TL;DR: This chapter examines likely root causes and the vigorous response in many areas of drug discovery, including improved target identification and validation technologies, network pharmacology, greater collaborative ways of working and use of biomarkers and patient stratification.
The epidemiology of acute asthma managed by ambulance paramedics in the prehospital setting in Western Australia
TL;DR: A review of clinical features, diagnosis, treatment, and hospital care of Asthma in Australia and abroad: a review of outcome studies, 2.6.3 CONTENTS 6 MEDICAL ABBREVIATIONS and DEFINITIONS 9 STATISTICAL AB BREVIations and de defines 11
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.